department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Soliris · pharmadog

pharmadog
drugs
Soliris

drug

patient view →

eculizumab

Marketedupdated 2mo ago

by Alexion Pharmaceuticals Inc

Approved

annual revenue · 2024–2024peak $3.1B

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Soliris

generic

eculizumab

indication

Paroxysmal Nocturnal Hemoglobinuria

phase

marketed

approved

2007-03-16

Data sources

openFDA · ClinicalTrials.gov

last refreshed just now

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 6

tagApproval34 co-mentions · 17 sources
drugBKEMV24 co-mentions · 17 sources
drugEPYSQLI20 co-mentions · 10 sources
companySamsung Bioepis Co Ltd10 co-mentions · 10 sources
drugeculizumab biosimilar7 co-mentions · 7 sources
company$AMGNAMGEN INC7 co-mentions · 7 sources

Trials studying eculizumab

phase3Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in Chinacompletedn=25
phase3A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatmentactive not recruitingn=202
phase2Study of NM8074 in Adult PNH Patients With Inadequate Response to Solirisnot yet recruitingn=12
phase3A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitorsactive not recruitingn=210
—Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Dataactive not recruitingn=50
phase3A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitorsactive not recruitingn=190
phase3Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMGcompletedn=15
phase3A Phase III Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapycompletedn=73

more trials →